Sensus Healthcare Announces Strong 2024 Financial Results

Sensus Healthcare, Inc. ( (SRTS) ) has released its Q4 earnings. Here is a breakdown of the information Sensus Healthcare, Inc. presented to its investors.

Sensus Healthcare, Inc. is a medical device company that specializes in non-invasive treatments for skin cancer and keloids using superficial radiotherapy technology. The company operates within the healthcare sector, focusing on providing cost-effective and adaptable treatment solutions.

Sensus Healthcare recently reported its financial results for the fourth quarter and full year of 2024, highlighting a record shipment of SRT systems and a notable revenue increase. The company continues to show consistent profitability and has expanded its international market presence.

Key financial metrics from the report indicate that Sensus Healthcare achieved quarterly revenues of $13.1 million, marking a 4% increase from the previous year, and annual revenues of $41.8 million, up 71% year-over-year. The company reported a net income of $1.5 million for the quarter, translating to $0.09 per diluted share. Additionally, Sensus shipped a record 39 SRT systems during the fourth quarter and 115 systems throughout 2024, reflecting significant growth in unit sales.

Sensus Healthcare concluded the year with $22.1 million in cash and no debt, positioning itself well for future growth initiatives. The company is actively pursuing new revenue-sharing agreements and plans to continue showcasing its innovative technology at major industry conferences.

Looking ahead, Sensus Healthcare’s management remains focused on growth and profitability by enhancing market access and expanding its product portfolio. While expecting a potentially softer first quarter in 2025, the company anticipates overall sales growth for the year, driven by strategic initiatives and new market opportunities.